poster

Psychedelics and Wellness Study (PAWS): Psychedelic Use and Its Impact on Long-term Wellness and Holistic Mental Health & Behavioral Markers – Results From an Online Anonymous Nationwide Survey of Adults

OBJECTIVE: This survey intends to fill a research and educational gap by conducting an in-depth anonymous online survey of U.S. adults, investigating the impact of past psychedelic use an...

11/22/2019

Efficacy (NNT) and Tolerability (NNH) of Cariprazine in Bipolar Disorder

Background: Cariprazine is approved to treat manic, mixed, and depressive symptoms of bipolar I disorder. This analysis describes the efficacy and tolerability of cariprazine in bipolar I...

11/22/2019

Extended-Release Viloxazine (SPN-812) 100 mg or 200 mg for the Treatment of ADHD in Children: Topline Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301)

Background: SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) being developed as a treatment for attention-defic...

11/22/2019

Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant Antidepressant: Post Hoc Analysis of Four Short-Term Studies

Background: We aimed to determine the effects of adjunctive brexpiprazole on sexual functioning in adults with major depressive disorder (MDD), according to antidepressant treatment (ADT)...

11/22/2019

Lumateperone in the Treatment of Schizophrenia: Efficacy in Demographic and Clinical Subgroups

Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...

11/22/2019

Risk of Subsequent Relapses and Corresponding Healthcare Costs Among Recently-Relapsed Medicaid Patients With Schizophrenia

BACKGROUND: Schizophrenia relapses can cause a significant increase in healthcare resource utilization and costs. However, the risk of relapse may be different between patients initiated ...

11/22/2019

Economic Burden of Treatment Resistant Depression in Privately Insured US Patients With Behavioral Comorbidities

BACKGROUND: Incremental economic burden of treatment resistant depression (TRD) in patients with behavioral comorbidities is largely unknown.

11/22/2019

Relationship Between ADHD Symptom and Executive Function Improvement in Adult ADHD in SHP465 Mixed Amphetamine Salts Extended-Release Clinical Trials

Adult attention-deficit/hyperactivity disorder (ADHD) is associated with impaired executive function (EF). This post hoc analysis examines relationships between changes in ADHD symptoms a...

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

11/22/2019

Post Hoc Responder Analyses of SHP465 Mixed Amphetamine Salts Extended-Release Among Adults With Attention-Deficit/Hyperactivity Disorder

In adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release reduced ADHD-Rating Scale-IV total score (ADHD-RS-IV-TS) significantl...

11/22/2019

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products